/biz/ - Business & Finance

All aboard the Zoetis rocket.
>314% growth since 2013
>recession-proof global industry.
>high ROIC
>diverse new product areas
> Zoetis generates roughly twice the revenue and 16x the profits of its closest competitor Elanco
>isn't too reliant on blockbuster brands, nor acquisitions, nor new products for growth. Instead, it's proving capable of maximizing the returns of each.

Zoetis is developing a pipeline of monoclonal antibodies to treat pain in dogs. Biologic drugs such as these are normally only used for humans but people tend to go to great lengths for their pets, and with significantly less regulatory oversight than human therapies this venture could well be a huge breakthrough in animal healthcare

We mooning now